ASP Isotopes Inc. (NASDAQ:ASPI) Sees Significant Increase in Short Interest

ASP Isotopes Inc. (NASDAQ:ASPI) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 15,300,000 shares, a growth of 104.3% from the January 15th total of 7,490,000 shares. Based on an average daily trading volume, of 3,810,000 shares, the days-to-cover ratio is presently 4.0 days. Currently, 28.2% of the company’s shares are short sold.

Hedge Funds Weigh In On ASP Isotopes

Large investors have recently modified their holdings of the company. Hanson & Doremus Investment Management purchased a new position in shares of ASP Isotopes in the 4th quarter worth about $27,000. Avantax Advisory Services Inc. purchased a new position in shares of ASP Isotopes in the 4th quarter worth about $45,000. Russell Investments Group Ltd. raised its holdings in shares of ASP Isotopes by 56.3% in the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock worth $46,000 after purchasing an additional 3,682 shares during the period. SVB Wealth LLC purchased a new position in shares of ASP Isotopes in the 4th quarter worth about $49,000. Finally, Boston Financial Mangement LLC purchased a new position in shares of ASP Isotopes in the 4th quarter worth about $50,000. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

ASP Isotopes Price Performance

ASP Isotopes stock opened at $5.57 on Thursday. The stock’s 50-day moving average is $5.22 and its 200-day moving average is $4.44. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. ASP Isotopes has a 12 month low of $1.86 and a 12 month high of $9.33.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reiterated a “buy” rating and set a $4.50 target price on shares of ASP Isotopes in a research report on Friday, October 18th.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.